Nanomerics is pleased to announce signing of a collaboration agreement with UCL School of Pharmacy, the University of Exeter Physics Department and AMTechnoloy. The £1.2M research contract will fund pharmacological and drug development research on Nanomerics pain therapeutic - METDoloron. METDoloron is an oral peptide pain therapeutic enabled by
Nanomerics' Molecular Envelope Technology. The peptide acts on specific receptors in the brain and Nanomerics' Molecular Envelope Technology enables the peptide to be absorbed when taken by mouth and reach the brain receptors. Peptides are usually destroyed in the gut or destroyed in the blood and do not normally reach the brain in sufficient quantity to elicit a pharmacological response. METDoloron, by acting on alternative pain receptors should have a superior safety profile to existing pain medicines. The Nanomerics - universities contract is a component of a larger TSB - EPSRC funding package worth £1.2M along with additional matched private sector funding of £450,000.
"We are absolutely delighted to have concluded the contract with these two world class universities and look forward to accessing the scientific expertise of these academics and furthering our product development," says Nanomerics CEO Dr Andreas Schatzlein.